190783-99-4

Basic information

• Product Name: 1-Methyl-5-oxoproline methyl ester
• Synonyms: Proline, 1-methyl-5-oxo-, methyl ester (9CI);Proline, 1-methyl-5-oxo-, methyl ester;1-Methyl-5-oxoproline methyl ester;Methyl 1-Methyl-5-oxopyrrolidine-2-carboxylate
• CAS NO: 190783-99-4
• Molecular Formula: C₇H₁₁NO₃
• Molecular Weight: 157.17
• Product Categories: PYRROLE;CARBOXYLICESTER;Heterocycles
• Mol File: 190783-99-4.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 264 ºC
• Flash Point: 113 ºC
• Appearance: /
• Density: 1.173
• Vapor Pressure: 0.0101mmHg at 25°C
• Refractive Index: 1.476
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-Methyl-5-oxoproline methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-5-oxoproline methyl ester(190783-99-4)
• EPA Substance Registry System: 1-Methyl-5-oxoproline methyl ester(190783-99-4)

Safety Data

• Hazardous Substances Data: 190783-99-4(Hazardous Substances Data)

Usage

General Description

1-Methyl-5-oxoproline methyl ester is a chemical compound with the molecular formula C6H9NO3. It is a methyl ester derivative of 1-methyl-5-oxoproline, and is used in the synthesis of various pharmaceuticals, pesticides, and other organic compounds. This chemical is a white solid with a melting point of 81-83°C, and is commonly used as a reagent in organic chemistry reactions. It can also be used as a building block in the synthesis of pyrrolidinone derivatives, which have potential applications in medicinal chemistry. 1-Methyl-5-oxoproline methyl ester is used as a starting material in the production of various pharmaceuticals, pesticides, and other organic compounds.

InChI:InChI=1/C7H11NO3/c1-8-5(7(10)11-2)3-4-6(8)9/h5H,3-4H2,1-2H3/t5-/m0/s1

Upstream product

• 4931-66-2 methyl (S)-pyroglutamate 
• 137414-32-5 5-Methoxy-3,4-dihydro-2H-pyrrole-2-carboxylic acid methyl ester; compound with sulfuric acid monomethyl ester 
• 77-78-1 dimethyl sulfate 
• 4931-66-2 methyl 5-oxopyrrolidine-2-carboxylate 
• 149-87-1 Pyroglutamic acid 
• 74-88-4 methyl iodide 
• 137131-35-2 5-methoxy-3,4-dihydro-2H-pyrrole-2-carboxylic acid methyl ester 
• 98-79-3 L-Pyroglutamic acid 
• 1262525-57-4 (3aS,9aS,3S)-2,3,3a,4,9,9a-hexahydro-4-[(1S)-1-methoxyethyl]-2-methyl-4,9-[1',2']benzeno-1H-benzo[f]isoindol-1-one-3-carboxylic acid methyl ester 

Downstream Products

• 52574-06-8 (2S)-1-methyl-5-oxopyrrolidine-2-carboxylic acid 
• 37619-24-2 methyl N-methylpyrrole-2-carboxylate 
• 56453-96-4 5-Chlor-1-methyl-pyrrol-2-carboxaldehyd 
• 51102-42-2 8-methyl-3,8-diazabicyclo[3,2,1]octane 
• 63978-04-1 3-benzhydryl-8-methyl-3,8-diaza-bicyclo[3.2.1]octane 
• 72442-37-6 1-methyl-5-oxopyrrolidine-2-carboxylic acid 
• 1200-94-8 3,4,5-Trichlor-1-methyl-1H-pyrrol-2-carbonsaeure-methylester 
• 1196-08-3 5-chloro-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester 
• 1198-72-7 4,5-Dichlor-1-methyl-1H-pyrrol-2-carbonsaeure-methylester 

Relevant articles and documents

BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION

The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto- temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Novel Receptor Antagonists and Their Methods of Use

The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.